Clarity Pharmaceuticals Completes Final Follow-Ups in Key Prostate Cancer Imaging Trial
Event summary
- Clarity Pharmaceuticals has completed all follow-up assessments in its Phase III AMPLIFY trial for 64Cu-SAR-bisPSMA, a diagnostic imaging agent for prostate cancer recurrence.
- The trial, which began in May 2025, enrolled 220 participants across the US and Australia, with the last patient assessed in November 2026.
- 64Cu-SAR-bisPSMA has received Breakthrough Therapy designation from the FDA, expediting its development and review process.
- Topline data from AMPLIFY and the parallel CLARIFY trial are expected in the first half of 2027, with NDA submissions to follow under the FDA's rolling review process.
The big picture
Clarity Pharmaceuticals' completion of the AMPLIFY trial marks a critical step in validating its next-generation PSMA PET imaging technology. The FDA's Breakthrough Therapy designation underscores the unmet need for improved diagnostic tools in prostate cancer recurrence, positioning Clarity to compete in a rapidly evolving radiopharmaceutical landscape. The company's ability to leverage this momentum will depend on the strength of its clinical data and execution in regulatory and commercialization strategies.
What we're watching
- Regulatory Momentum
- Whether the Breakthrough Therapy designation will accelerate FDA approval and commercialization timelines for 64Cu-SAR-bisPSMA.
- Market Opportunity
- The pace at which Clarity can capture share in the growing prostate cancer imaging market, projected to exceed $3Bn by 2029.
- Clinical Validation
- How topline data from AMPLIFY and CLARIFY will compare to existing PSMA PET imaging agents in terms of diagnostic performance.
Related topics
